Click on headlines below to download research
ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While…
ReNeuron’s FY23 results provide a recap of financial and operational highlights from the period. Following the restructuring announcement in January…
ReNeuron Group has presented encouraging preclinical data surrounding the company’s conditionally immortalised induced pluripotent stem cell (CI…